Connor, Clark & Lunn Investment Management (CC&L)’s Albany Molecular Research Inc AMRI Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-105,242	Closed	-$2.32M	–	675
2014 Q3	$2.32M	Sell	105,242 -4,500	-4%	-$92.1K	0.02%	200
2014 Q2	$2.35M	Sell	109,742 -58,800	-35%	-$996K	0.02%	230
2014 Q1	$3.46M	Buy	168,542 +14,800	+10%	+$204K	0.03%	201
2013 Q4	$1.65M	Buy	153,742 +50,788	+49%	+$614K	0.01%	288
2013 Q3	$1.36M	Buy	102,954 +38,000	+59%	+$467K	0.01%	237
2013 Q2	$813K	Buy	+64,954	New	+$704K	0.01%	287

Other funds holding AMRI

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

EWM

Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AMRI Position: Q4 2014 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Albany Molecular Research Inc (AMRI) in Q4 2014, closing a stake of 105,242 shares — an estimated $2.32M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AMRI in Q2 2013 and held it in 6 quarters. The position peaked at $3.46M in Q1 2014. 132 funds tracked by Wall St. Rank hold AMRI as of Q4 2014.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Albany Molecular Research Inc position as of Q4 2014 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 105,242 Albany Molecular Research Inc shares in Q4 2014, an estimated $2.32M.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 6 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s Albany Molecular Research Inc position peaked at $3.46M in Q1 2014.
132 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q4 2014.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2014, filed 12 Feb 2015.